Drugs / CRX100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04282044 | Jan 2021 → Aug 2025 overdue | colorectal cancer, gastric cancer, hepatocellular carcinoma, malignant epithelial tumor of ovary +4 | BioEclipse Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-03-19 | BioEclipse Therapeutics | Results CRX100 Elicits Activity, Is Well Tolerated in Recurrent, Platinum-Resistant Ovarian Cancer bioeclipse.com ↗
Combination treatment with the novel adoptive Natural Killer-Like T (NK-T) cell therapy CRX100 and a tumor-specific oncolytic vaccinia virus generated responses and was well tolerated in a small cohort of patients with recurrent, platinum-resistant ovarian cancer, according to data from a phase 1 trial (NCT04282044) presented at the 2024 SGO Annual Meeting on Women’s Cancer. |
| 2020-04-28 | BioEclipse Therapeutics | Regulatory BioEclipse Receives FDA Clearance of Investigational New Drug Application for CRX100 bioeclipse.com ↗
BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company developing first-in-class, curative immuno-oncology therapeutics, announced today that the U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for the Company’s lead drug candidate, CRX100. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-03-19 | BioEclipse Therapeutics | CRX100 Elicits Activity, Is Well Tolerated in Recurrent, Platinum-Resistant Ovarian Cancer bioeclipse.com ↗ |
| 2022-04-26 | BioEclipse Therapeutics | BioEclipse Therapeutics™ Awarded Almost $8 Million Grant by California Institute for Regenerative Medicine (CIRM) to Fund Ongoing Phase 1 CRX100 Cancer Immunotherapy Clinical Trial bioeclipse.com ↗ |
| 2021-01-19 | BioEclipse Therapeutics | BioEclipse Initiates Enrollment in Phase 1 Dose-Escalation Clinical Trial for CRX100 at HonorHealth Research Institute bioeclipse.com ↗ |
| 2020-12-21 | BioEclipse Therapeutics | BioEclipse Initiates Enrollment in Phase 1 Dose-Escalation Clinical Trial for CRX100 bioeclipse.com ↗ |
| 2020-04-28 | BioEclipse Therapeutics | BioEclipse Receives FDA Clearance of Investigational New Drug Application for CRX100 bioeclipse.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRX100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04282044 ↗ |